ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > PMN update- 2020 in review

<< Previous

Bullboard Posts

Next >>

Comment by M101on Dec 14, 2020 1:25pm

109 Views

Post# 32100857

RE:RE:PMN update- 2020 in review

At least Elliot is being consistent. I mean the only other reason he can't raise cash short of a half-price sale is because of Biogen's "mistake".
"The negative advisory committee vote will most likely impact the AD field for some time in 2021, including the very challenging capital formation environment that we and others have faced in this field since Biogen’s mistaken suspension of the aducanumab program in March 2019"

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market